Tenofovir (TFV) and emtricitabine (FTC) are under study in combination for HIV prophylaxis. TFV and FTC belong to the nucleoside analog reverse transcriptase inhibitors (NRTls) drug class, which undergoes sequential phosphorylation in patients to the intracellular triphosphate anabolite. The pharmacologic activity of NRTls depends on the triphosphate, which inhibits HIV reverse transcriptase to elicit pharmacologic effect. The phosphorylated anabolites are ionized and trapped within cells, which leads to differing pharmacokinetics compared with the parent drug in plasma. The dosing of NRTls in patients is guided by the intracellular profile of the active triphosphates, which demonstrates the human health importance of NRTl cellular pharmacology information. HIV prophylaxis is a new use for TFV and FTC in a new patient group (HIV-negative persons). Cellular pharmacology data are needed to support and guide this new use, but this information has not been generated. It is not acceptable to extrapolate intracellular information from HIV positive patients under treatment for chronic HIV-infection because this is a different patient group and treatment scenario. In fact, the patient groups have different cellular activation states and different pharmacodynamic considerations exist for prophylaxis compared with treatment of chronic HIV. The studies proposed herein will provide cellular pharmacology data relevant to HIV prophylaxis. The main goals are: to characterize and compare the intracellular profiles of TFV and FTC in HIV-negative versus HIV-positive adults;to identify a prophylactic threshold for intracellular TFV and FTC in HIV-negative adults;to develop a comprehensive pharmacokinetic model for intracellular TFV and FTC to predict the optimal dose and onset and duration of prophylactic action;and to evaluate whether the pharmacologic spectrum of TFV includes inhibition of purine nucleoside phosphorylase in vivo. The application addresses our long term goal to promote the optimal use of TFV and FTC for HIV prevention and treatment through rational dosing strategies founded on TFV and FTC cellular pharmacology in patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI084735-03
Application #
8136242
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M4))
Program Officer
Chow, Grace C
Project Start
2009-08-15
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
3
Fiscal Year
2011
Total Cost
$2,159,561
Indirect Cost
Name
University of Colorado Denver
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Chen, Xinhui; McAllister, Kevin J; Klein, Brandon et al. (2017) Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate. Biomed Chromatogr 31:
Zheng, Jia-Hua; Rower, Caitlin; McAllister, Kevin et al. (2016) Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal 122:16-20
Gandhi, Monica; Glidden, David V; Mayer, Kenneth et al. (2016) Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV 3:e521-e528
Castillo-Mancilla, Jose; Seifert, Sharon; Campbell, Kayla et al. (2016) Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother 60:6692-6697
Glidden, David V; Anderson, Peter L; Grant, Robert M (2016) Pharmacology supports on-demand PrEP. Lancet HIV 3:e405-e406
Chen, Xinhui; Castillo-Mancilla, Jose R; Seifert, Sharon M et al. (2016) Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrob Agents Chemother 60:5387-92
Seifert, Sharon M; Glidden, David V; Meditz, Amie L et al. (2015) Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis 60:804-10
Gandhi, Monica; Glidden, David V; Liu, Albert et al. (2015) Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. J Infect Dis 212:1402-6
Castillo-Mancilla, Jose R; Searls, Kristina; Caraway, Patricia et al. (2015) Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses 31:428-32
Monte, Andrew A; Anderson, Peter; Hoppe, Jason A et al. (2015) Accuracy of Electronic Medical Record Medication Reconciliation in Emergency Department Patients. J Emerg Med 49:78-84

Showing the most recent 10 out of 25 publications